Barbara Hero

Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas (2008)

Westermann, Frank, Muth, Daniel, Benner, Axel, Bauer, Tobias, Henrich, Kai-Oliver, Oberthuer, André, ...

Abstract Background Amplified MYCN oncogene resulting in deregulated MYCN transcriptional activity is observed in 20% of neuroblastomas and identifies a highly aggressive subtype. In MYCN single-copy...

Featured Article The Tumor-Associated Antigen PRAME Is Universally Expressed in High-Stage Neuroblastoma and Associated with Poor Outcome (2008)

André Oberthuer, Barbara Hero, Rüdiger Spitz, Frank Berthold, Matthias Fischer

Purpose: The tumor-associated antigen PRAME, a potential candidate for immunotherapeutic targeting, is frequently expressed in a variety of cancers. However, no information about its presence in...

Gene-expression based classification of neuroblastoma patients using a customized oligonucleotide-microarray outperforms current clinical risk stratification (2006)

Oberthuer, André, Berthold, Frank, Warnat, Patrick, Hero, Barbara, Kahlert, Yvonne, Spitz, Rüdiger, ...

PURPOSE: To develop a gene expression–based classifier for neuroblastoma patients that reliably predicts courses of the disease. PATIENTS AND METHODS: Two hundred fifty-one neuroblastoma specimens...

Full-Length Telomerase Reverse Transcriptase Messenger RNA Is an Independent Prognostic Factor in Neuroblastoma

Krams, Matthias, Hero, Barbara, Berthold, Frank, Parwaresch, Reza, Harms, Dieter, Rudolph, Pierre

Telomerase activity (TA) is the most recently recognized prognostic factor in neuroblastoma, and its outstanding predictive power was documented by several studies. However, TA measurements require...

Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas

Westermann, Frank, Muth, Daniel, Benner, Axel, Bauer, Tobias, Henrich, Kai-Oliver, Oberthuer, André, ...

Differences in MYCN/c-MYC target gene expression are associated with distinct neuroblastoma subtypes and clinical outcome.